Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, US$ 26.72 Min. order: 1 piece ★★★★★ 4.0 (272 reviews) Sold : Login>>
Emerging pharmacotherapies for obesity: A systematic review US$ 26.38 Min. order: 1 piece ★★★★★ 4.6 (111 reviews) Sold : Login>>
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management - Alhomoud - 2024 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy US$ 22.92 Min. order: 1 piece ★★★★★ 4.0 (242 reviews) Sold : Login>>